Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3Kδ inhibitors
Authors:
- 1 October 2019
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 27 (19) , 115035
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Shaanxi Province
This publication has 18 references indexed in Scilit:
- Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune DiseasesJournal of Medicinal Chemistry, 2018
- Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry PerspectiveJournal of Medicinal Chemistry, 2018
- Duvelisib: First Global ApprovalDrugs, 2018
- Can umbralisib bring PI3Kδ out of the shadows?The Lancet Oncology, 2018
- Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective InhibitorsACS Medicinal Chemistry Letters, 2017
- Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective InhibitorsACS Medicinal Chemistry Letters, 2016
- Targeting PI3Kδ: Emerging Therapy for Chronic Lymphocytic Leukemia and BeyondMedicinal Research Reviews, 2015
- Idelalisib: First Global ApprovalDrugs, 2014
- Idelalisib — A PI3Kδ Inhibitor for B-Cell CancersNew England Journal of Medicine, 2014
- Targeting the phosphoinositide 3-kinase pathway in cancerNature Reviews Drug Discovery, 2009